Aktuella utlysningar, vecka 19, 2019
Grants Office tipsar om aktuella utlysningar
Svenska och nordiska utlysningar
Apparaturanslag – Parkinson Foundation in Sweden
Parkinsonfonden inbjuder ansökningar om apparaturanslag. Dessa möjliggör inköp av medeldyr apparatur eller apparatur som inte är av baskaraktär. Behöriga att söka är disputerade forskare som har hel- eller deltidstjänst vid ett svenskt universitet eller sjukhus. Anslag uppgår till SEK 300,000 var och söks för ett år i taget.
Closing date: 1 June 2019
Forskningsanslag – Gunvor och Josef Anérs Stiftelse
Gunvor och Josef Anérs stiftelse inbjuder ansökningar om forskningsanslag. Dessa stödjer vetenskaplig forskning med företräde för humanistiska forskningsgrenar. Projekt kan beröra följande områden: humanistiska och samhällsvetenskapliga forskningsområden, värt minst 15 procent och högst SEK 150,000 av den totala projektsumman; medicinska forskningsområdet, värt minst 15 procent av den totala projektsumman.
Closing date: 1 June 2019
Nordic workshops – Joint Committee of the Nordic Research Councils for Humanities and Social Sciences
The Joint Committee for Nordic Research Councils for the Humanities and the Social Sciences (NOS-HS) and the Swedish Research Council invite proposals for their Nordic workshop series. These promote research collaboration and development of new research areas and programmes within the humanities and social sciences in the Nordic countries through a series of workshops. Individual researchers based in Nordic countries may apply. They must hold a doctoral degree or equivalent. The grant must be administered by a Nordic HEI, research institute or public organisation with which the project leader is affiliated. The project leader must involve at least two and at most six co-applicants from two other different Nordic countries in their application. Grants are worth between €29,000 and €43,000 each for two years.
Closing date: 3 June 2019
Postdoktoralt stöd för studier och forskning inom området hälsa – AFA Insurance
AFA Försäkring inbjuder ansökningar om stipendium för postdoktorala studier och forskning inom området hälsa. Detta syftar till att bidra till kompetensutveckling inom hälsoområdet med inriktning rehabilitering och återgång i arbete genom att ge nyligen disputerade ökade möjligheter till postdoktorala studier och forskning. En längre period av stödperiden bör genomföras vid ett utländskt lärosäte. Stipendiet kan sökas av personer som har disputerat under de senaste tre åren eller kommer att göra det senast 1 september 2019. Forskare verksamma vid svenska universitet, högskolor, forskningsinstitut eller universitetssjukhus är behöriga att söka, men behöver inte vara anställda vid ansökningstillfället. Medel omfattar SEK 2 miljoner och stipendiet kan utnyttjas under en tvåårsperiod med början den 1 januari 2020.
Closing date: 17 June 2019
Research grants for prevention of animal testing – Swedish Fund for Research Without Animal Experiments
The Swedish Fund for Research Without Animal Experiments invites applications for its research grants for the prevention of animal testing. These support scientific research aimed at replacing animal experiments. Innovative research of any kind on this topic is welcome, including in vitro models, epidemiological studies, clinical research, system biology and calculation models. Applications relating to the analysis of existing patient data and other knowledge obtained from humans, applications with a focus on biomarkers and biomechanisms and projects aimed at developing products or methods that can replace animal products are also welcome. The projects must be performed in Sweden or include Swedish participants.
Closing date: 27 June 2019
The Olav Thon Foundation – support for Nordic research projects in medicine 2020
The Foundation will reserve NOK 20 million for grants to Nordic research collaboration in the field of medicine for 2020. Only researchers associated with universities or academic institutions in the Nordic countries are eligible for support. Previous collaboration will be regarded as an advantage and should be documented (by co-publications or similar). The collaboration must include specific research groups in at least two Nordic countries and be led by personnel holding professorships or equivalent permanent academic positions.
Applications will be assessed in light of their academic quality and the projects’ potential for development of new and groundbreaking knowledge in medicine. For 2020, the Board of the Foundation has decided to invite applications for research on reparative medicine targeting diseases in the musculoskeletal and peripheral and central nervous system. Projects should be based on the use of stem cell biology, genetic approaches, tissue engineering, biotechnology, or regenerative medicine with the aim of repairing, regrowing or replacing damaged or diseased cells or tissues. Research support for each project is restricted to a maximum of NOK 2.5 million per year for a maximum of four years.
Closing date: 15 September 2019
Marie Skłodowska Curie Actions Individual Fellowships 2019
MSCA-IF are postdoc fellowships, for a project within Europe with a 2-year European Fellowship, or outside Europe (2 years) with a mandatory 1-year return phase to Europe with the 3-year Global Fellowship. Applicants are fellows with an identified PI and Host Organisation. The fellows should have a PhD degree or equivalent four years full-time research experience by the time of deadline 2019-09-11. Grants are typically up to €203,852 for two years for incoming fellowships to Sweden and used for salary and allowances for the fellow; research and overhead.
Closing date: 11 September 2019.
ERC-2019-AdG advanced grants -- Horizon 2020: Excellent Science, EU
These support ground-breaking high-risk projects carried out by an established, leading principal investigator in any field of research. Applicants are expected to be active researchers who have a track-record of significant research achievements in the last 10 years, and should be exceptional leaders in terms of originality and significance of their research contributions.
Approximately 166 grants are available, each worth up to €2.5m, over five years. An additional €1m may be requested.
Deadline information: Proposals are invited between 21 May and 29 August 2019.
Academic-led clinical studies in drug discovery -- Alzheimer's Society, GB and other funders
The Alzheimer’s Society and Alzheimer’s Drug Discovery Foundation invite letters of intent for their academic-led clinical studies in drug discovery call. This supports therapeutic approaches for early-stage drug discovery and clinical development for Alzheimer’s disease, related dementias and cognitive ageing. The call specifically targets novel drug programmes aiming to advance novel lead molecules to the clinical candidate stage, including small molecules and biologics; and repurposed or repositioned programmes aiming to build preclinical evidence in relevant animal models for repurposed drugs.
Researchers and clinicians worldwide who are based at academic medical centres, universities, non-profit organisations or biotechnology companies may apply. Funding is worth between USD 150,000 and USD 600,000 for one year, the potential for follow-on funding.
Closing date: 12 July 2019. Letters of intent due by 5pm ET, 12 April; invited full proposals due by 5pm ET, 10 May 2019.
Albert Renold travel fellowships -- European Association for the Study of Diabetes, EUR
These enable scientists and clinicians to travel and stay at other institutions in order to learn specific scientific techniques or clinical skills required for the advancement of their diabetes research project that are not available at their home institution. Either the home or the host institution must be based in Europe or an associated country, and the host institution must be in a different country from the home institution.
Awards are worth up to €8,000 each over up to three months.
Closing date: 15 July 2019 (Deadlines on 15 April 2019, 15 July 2019, 15 October 2019, 15 January 2020, and repeated annually.)
Open call – public health issues -- Enhancing Learning and Research for Humanitarian Assistance, GB
This supports research that will strengthen the evidence base around public health interventions, rendering them more effective in humanitarian crises.
Applicants must have a research team including both a research institution and an operational humanitarian organisation. Collaboration between northern and southern research institutions and researchers is viewed favourably.
The budget is worth up to £3.5 million; however, there is no ceiling on the amount that can be requested. The maximum funding duration is three years. Shortlisted applicants each receive seed funding worth £10,000 to support the development of research partnerships and to finalise proposal development.
Closing date: 17 July 2019 (Forecast; we have no information from the funder yet about the next call. Based on past experience, we forecast the deadline to be around July 2019. This call is repeated once a year.)
Liliane Bettencourt prize for life sciences -- Bettencourt Schueller Foundation, FR
The Bettencourt Schueller Foundation invites applications for the Liliane Bettencourt prize for life science. This recognises a European researcher in the life sciences. Applicants must be under 45 years of age on 1 January 2019, be EU nationals and work in a laboratory located in an EU or EFTA country.
The prize is worth €300,000, of which €100,000 is given to the researcher and €200,000 is given to the organisation managing the laboratory hosting the research project.
Closing date: 23 July 2019 (Forecast; we have no information from the funder yet about the next call. Based on past experience, we forecast the deadline to be around July 2019. This call is repeated once a year.)
Federal Funding agencies
Lucidity in Dementia (R21 Clinical Trial Optional): NIH
This FOA is intended to advance scientific understanding of lucidity in dementia by supporting an initial set of retrospective and/or prospective studies that will lay the groundwork for further research on this topic. Studies supported by this FOA will use the R21 mechanism to support initial exploratory/developmental aims that will serve as the foundation for future studies.
Results from studies supported by this FOA have the potential to broaden our conceptual understanding of Alzheimer’s disease and related dementias. Current models of progression and functional decline do not adequately account for spontaneous reversals of cognitive ability – even transiently – in late-stage disease. Further study of lucid episodes in dementia could potentially expand existing paradigms and inform novel approaches for future studies. Greater understanding of lucidity in dementia may also influence families’ and caregivers’ attitudes and behaviors toward patients with dementia, advance understanding of personhood throughout the course of dementia, and address ethical challenges or decisional conflicts among family members or other proxies who witness lucid episodes.
Closing date: February 3, 2020, by 5:00 PM local time of applicant organization.
Funding Opportunity Announcement (FOA): RFA-AG-20-016
Imaging, Biomarkers and Digital Pathomics for the Early Detection of Premetastatic Aggressive Cancer (R01 Clinical Trial Optional): NIH
This Funding Opportunity Announcement (FOA) will support the development of state-of-the-art projects that include imaging, biomarkers, digital pathomic and other -omic integration strategies for improving current approaches for the earliest detection of premetastatic aggressive cancer as well as identifying precancerous lesions that will subsequently demonstrate an aggressive phenotype. This FOA specifically attempts to address and improve diagnostic uncertainty in clinical decisions in a technology agnostic manner by improving sensitivity and specificity of applied tests. N-dimensional co-registered, cross-correlated imaging results integrated with multiplexed biomarker data and digital pathomics using analytic strategies such as artificial intelligence and virtual reality visualization for improving discovery are encouraged. The projects supported by this FOA will collectively participate in the existing Consortium for Imaging and Biomarkers (CIB) Research Program. The goals of the CIB are to: (1) improve diagnostic performance by developing methodology for the early identification of lethal cancer versus non-lethal disease, (2) to minimize/better manage overdiagnosis and (3) to reduce false positives and false negatives.
Closing date: December 10, 2019; July 10, 2020; December 10, 2020; July 9, 2021; December 10, 2021, by 5:00 PM local time of applicant organization.
Funding Opportunity Announcement (FOA): PAR-19-264
Novel Nucleic Acid Sequencing Technology Development (R01 Clinical Trial Not Allowed): NIH
This Funding Opportunity Announcement (FOA) solicits R01 grant applications to develop novel technologies that will enable no less than one order of magnitude improvement in DNA sequencing, and practical methods for direct RNA sequencing. Advances in genomics and more broadly in biomedical research have been greatly facilitated by significant and sustained DNA sequencing throughput increases and cost decreases. The goal now is to improve the quality and efficiency of DNA sequencing and enable direct RNA sequencing (e.g., longer read lengths, faster turn-around time, greater accuracy, and higher-throughput etc.) at reasonable costs with the anticipation that significant advances in any of these and related areas would make significant contributions to the mission of NHGRI and the field of genomics, including to many of NHGRI’s other technology development goals.
Closing date: September 10, 2019; September 10, 2020 by 5:00 PM local time of applicant organization.
Funding Opportunity Announcement (FOA): RFA-HG-18-001 (R01), RFA-HG-18-002 (R21)
Selected Topics in Transfusion Medicine (R01 Clinical Trial Optional): NIH
This Funding Opportunity Announcement (FOA) encourages research grant applications from investigators who propose to study research topics in blood banking and transfusion medicine aimed at improving the safety and availability of the blood supply and the practice of transfusion medicine. Research focused on improving blood donor health, the safety and availability of blood products, and improving the practice of transfusion medicine is critical to public health. Research designed to better understand the determinants of transfusion-associated adverse events and how best to minimize transfusion risks is also important. Research is also needed to maintain an adequate blood supply by minimizing the risks associated with the donation process and developing enhanced recruitment and retention programs.
Closing date: October 5, 2019 by 5:00 PM local time of applicant organization. (January 7, 2020, by 5:00 PM local time of applicant organization. All types of AIDS and AIDS-related applications allowed for this funding opportunity announcement are due on these dates.)
Funding Opportunity Announcement (FOA): PAR-18-126 (R01), PAR-18-132 (R21)
Clinical Research Proposals, ResMed Foundation, US
The Foundation's key mission is to promote novel research as well as public and physician awareness of sleep disordered breathing (SDB), with a primary focus on positive airway pressure therapies and ventilation-based treatments. The Foundation will consider proposals focused on the evaluation, diagnosis, treatment and management of SDB and other respiratory disorders. Research areas of interest are also other morbidities that are associated with SDB which include cardiovascular disease, metabolic syndrome, diabetes and morbid obesity. In the cardiovascular area, there is a particular emphasis on hypertension, coronary artery disease, heart failure, and atrial fibrillation. Other areas of focus are: SDB in conjunction with occupational health safety, asthma and anesthesiology; chronic obstructive pulmonary disease; and, pregnancy/preeclampsia. Specific focus is on outcomes that can influence clinical practice in the near term.
Public and physician awareness of SDB is also an area of interest, however only programs that have wide outreach will be considered.
The Foundation is also interested in the application of novel screening and diagnostic tools to identify more easily SDB/OSA, as well as new and better paradigms to improve patient adherence and compliance with positive airway pressure and ventilation-based treatment methods.
Closing date: September 15, 2019
The Cancer Research Institute (CRI) Irvington Postdoctoral Fellowship Program, US
The CRI Irvington Postdoctoral Fellowship Program supports qualified young scientists at leading universities and research centers around the world who wish to receive training in fundamental immunology or cancer immunology. Fellows work and continue their training under the guidance of a world-renowned immunologist, who mentors the fellow and prepares him or her for a productive and successful career in cancer immunology.
Eligibility: Applicants for the CRI Irvington Postdoctoral Fellowship Program must
- Be working in areas directly related to immunology or cancer immunology.
- Have a doctoral degree by the date of award activation and must conduct their proposed research under a sponsor who holds a formal appointment at the host institution.
- Have 5 or more years of relevant postdoctoral experience are not eligible, with the exception of M.D. applicants, who should not include years of residency in this calculation.
- Only in exceptional circumstances will applicants who have already spent 3 or more years in a sponsor’s laboratory by the start date of fellowship be considered for a fellowship award.
Closing date: October 1, 2019 by 5 p.m. Eastern Time